ImmunityBio, Inc. (IBRX)
NASDAQ: IBRX · Real-Time Price · USD
7.32
+0.07 (0.97%)
At close: Aug 6, 2026, 4:00 PM EDT
7.33
+0.01 (0.14%)
After-hours: Aug 6, 2026, 7:59 PM EDT
ImmunityBio Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 165.79 | 113.29 | 14.75 | 0.62 | 0.24 | 0.93 | |
Revenue Growth | 192.92% | 668.32% | 2270.58% | 159.17% | -74.30% | 54.38% |
Cost of Revenue | 1.1 | 0.75 | - | - | - | - |
Gross Profit | 164.7 | 112.54 | 14.75 | 0.62 | 0.24 | 0.93 |
Selling, General & Admin | 172.6 | 150 | 168.78 | 129.62 | 102.71 | 135.26 |
Research & Development | 243.89 | 218.56 | 190.14 | 232.37 | 248.15 | 195.96 |
Other Operating Expenses | - | - | - | 0.89 | 0.68 | - |
Total Operating Expenses | 416.5 | 368.56 | 358.93 | 362.87 | 351.54 | 331.21 |
Operating Income | -251.8 | -256.03 | -344.18 | -362.25 | -351.3 | -330.28 |
Interest Income | 9.83 | 6.41 | 7.98 | 1.13 | -3.09 | -4.1 |
Interest Expense | -99.64 | -112.53 | -154.33 | -129.2 | -63.52 | -14.85 |
Other Non-Operating Income (Expense) | -634.46 | 10.54 | 76.89 | -93.58 | 0.62 | -0.61 |
Total Non-Operating Income (Expense) | -724.27 | -95.58 | -69.46 | -221.64 | -65.99 | -19.56 |
Pretax Income | -992.58 | -351.61 | -413.65 | -583.89 | -417.29 | -349.84 |
Provision for Income Taxes | -0.16 | -0.14 | - | -0.04 | 0.03 | 0.01 |
Net Income | -992.42 | -351.47 | -413.65 | -583.85 | -417.32 | -349.85 |
Minority Interest in Earnings | -0.06 | -0.07 | -0.08 | -0.66 | -0.75 | -3.06 |
Net Income to Common | -992.36 | -351.4 | -413.56 | -583.2 | -416.57 | -346.79 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 1,003 | 920 | 697 | 509 | 400 | 389 |
Shares Outstanding (Diluted) | 1,003 | 920 | 700 | 509 | 400 | 389 |
Shares Change | 26.45% | 31.33% | 37.71% | 27.19% | 2.74% | 3.23% |
EPS (Basic) | -0.97 | -0.38 | -0.59 | -1.15 | -1.04 | -0.89 |
EPS (Diluted) | -0.97 | -0.38 | -0.62 | -1.15 | -1.04 | -0.89 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -288.07 | -308.78 | -398.12 | -397.34 | -415.67 | -307.98 |
Free Cash Flow Growth | - | - | - | - | - | - |
Free Cash Flow Per Share | -0.29 | -0.34 | -0.57 | -0.78 | -1.04 | -0.79 |
Gross Margin | 99.34% | 99.34% | 100.00% | 100.00% | 100.00% | 100.00% |
Operating Margin | -151.88% | -226.00% | -2334.23% | -58239.50% | -146374.00% | -35361.90% |
Profit Margin | -598.59% | -310.25% | -2805.32% | -93866.90% | -173883.00% | -37457.00% |
FCF Margin | -173.76% | -272.56% | -2700.06% | -63881.20% | -173196.00% | -32974.50% |
EBITDA | -235.2 | -240.5 | -326.63 | -343.74 | -333.04 | -316.04 |
EBITDA Margin | -141.86% | -212.29% | -2215.18% | -55263.30% | -138766.00% | -33837.50% |
EBIT | -251.8 | -256.03 | -344.18 | -362.25 | -351.3 | -330.28 |
EBIT Margin | -151.88% | -226.00% | -2334.23% | -58239.50% | -146374.00% | -35361.90% |
Effective Tax Rate | 0.02% | 0.04% | 0.00% | 0.01% | -0.01% | -0.00% |